文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

AAV基因治疗杜氏肌营养不良:EMBARK 3期随机试验

AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.
PubMed 文献 · Nat Med · 2024-10-09

EMBARK 3期随机试验评估delandistrogene moxeparvovec治疗杜氏肌营养不良的疗效与安全性,纳入4至<8岁可行走男性患者,52周时主要终点NSAA评分变化未达统计学显著(组间差异0.65,95%CI -0.45,1.74;P=0.2441),部分次要终点数值上倾向于治疗组但无法声称统计学显著,安全性可控。

要点

  • 52周主要终点NSAA评分变化组间差异0.65(95%CI -0.45,1.74;P=0.2441),未达统计学显著。
  • 第12周平均微抗肌萎缩蛋白表达:治疗组34.29% vs 安慰剂组0.00%。
  • 7例(11.1%)患者发生10例治疗相关严重不良事件,无死亡、停药或临床显著补体介导不良事件。

核心结论

  • Delandistrogene moxeparvovec未能在第52周显著改善NSAA评分。
  • 部分次要终点数值上倾向于治疗组,但无法声称统计学显著。
  • 安全性可控,与既往delandistrogene moxeparvovec试验一致。

研究设计与样本

  • 3期EMBARK随机试验,纳入4岁至<8岁可行走男性杜氏肌营养不良患者。
  • 按年龄组和NSAA评分分层随机,单次静脉输注delandistrogene moxeparvovec(1.33×10^14载体基因组/千克;n=63)或安慰剂(n=62)。

主要发现

  • 第52周主要终点NSAA评分较基线变化最小二乘均值:治疗组2.57分 vs 安慰剂组1.92分,组间差异0.65(95%CI -0.45,1.74;P=0.2441)。
  • 第12周平均微抗肌萎缩蛋白表达:治疗组34.29% vs 安慰剂组0.00%。
  • 第52周次要终点组间差异(95%CI):起身时间-0.64(-1.06,-0.23),10米步行/跑-0.42(-0.71,-0.13),步速第95百分位0.10(0.00,0.19),100米步行/跑-3.29(-8.28,1.70),上4级台阶时间-0.36(-0.71,-0.01),PROMIS移动能力0.05(-0.08,0.19),PROMIS上肢能力-0.04(-0.24,0.17),NSAA技能获得/改善数量0.19(-0.67,1.06)。
  • delandistrogene moxeparvovec组记录674例不良事件,安慰剂组记录514例不良事件。
  • 无死亡、停药或临床显著补体介导不良事件;7例患者(11.1%)发生10例治疗相关严重不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 部分次要终点数值上倾向于治疗组,但无法声称统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Duchenne muscular dystrophy (DMD) is a rare, X-linked neuromuscular disease caused by pathogenic variants in the DMD gene that result in the absence of functional dystrophin, beginning at birth and leading to progressive impaired motor function, loss of ambulation and life-threatening cardiorespiratory complications. Delandistrogene moxeparvovec, an adeno-associated rh74-viral vector-based gene therapy, addresses absent functional dystrophin in DMD. Here the phase 3 EMBARK study aimed to assess the efficacy and safety of delandistrogene moxeparvovec in patients with DMD. Ambulatory males with DMD, ≥4 years to <8 years of age, were randomized and stratified by age group and North Star Ambulatory Assessment (NSAA) score to single-administration intravenous delandistrogene moxeparvovec (1.33 × 1014 vector genomes per kilogram; n = 63) or placebo (n = 62). At week 52, the primary endpoint, change from baseline in NSAA score, was not met (least squares mean 2.57 (delandistrogene moxeparvovec) versus 1.92 (placebo) points; between-group difference, 0.65; 95% confidence interval (CI), -0.45, 1.74; P = 0.2441). Secondary efficacy endpoints included mean micro-dystrophin expression at week 12: 34.29% (treated) versus 0.00% (placebo). Other secondary efficacy endpoints at week 52 (between-group differences (95% CI)) included: Time to Rise (-0.64 (-1.06, -0.23)), 10-meter Walk/Run (-0.42 (-0.71, -0.13)), stride velocity 95th centile (0.10 (0.00, 0.19)), 100-meter Walk/Run (-3.29 (-8.28, 1.70)), time to ascend 4 steps (-0.36 (-0.71, -0.01)), PROMIS Mobility and Upper Extremity (0.05 (-0.08, 0.19); -0.04 (-0.24, 0.17)) and number of NSAA skills gained/improved (0.19 (-0.67, 1.06)). In total, 674 adverse events were recorded with delandistrogene moxeparvovec and 514 with placebo. There were no deaths, discontinuations or clinically significant complement-mediated adverse events; 7 patients (11.1%) experienced 10 treatment-related serious adverse events. Delandistrogene moxeparvovec did not lead to a significant improvement in NSAA score at week 52. Some of the secondary endpoints numerically favored treatment, although no statistical significance can be claimed. Safety was manageable and consistent with previous delandistrogene moxeparvovec trials. ClinicalTrials.gov: NCT05096221.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Mendell JR, Muntoni F, McDonald CM, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2024. PMID: 39385046. doi:10.1038/s41591-024-03304-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。